Brooke S G Molina Selected Research

Combined Modality Therapy

2/2022	Variable Patterns of Remission From ADHD in the Multimodal Treatment Study of ADHD.
1/2022	Review: Adult Outcome as Seen Through Controlled Prospective Follow-up Studies of Children With Attention-Deficit/Hyperactivity Disorder Followed Into Adulthood.
1/2021	A Qualitative Analysis of Contextual Factors Relevant to Suspected Late-Onset ADHD.
12/2020	Childhood ADHD and Involvement in Early Pregnancy: Mechanisms of Risk.
1/2020	Trajectories of Growth Associated With Long-Term Stimulant Medication in the Multimodal Treatment Study of Attention-Deficit/Hyperactivity Disorder.
1/2020	Effects of Childhood and Adult Persistent Attention-Deficit/Hyperactivity Disorder on Risk of Motor Vehicle Crashes: Results From the Multimodal Treatment Study of Children With Attention-Deficit/Hyperactivity Disorder.
1/2020	Mutations in sphingolipid metabolism genes are associated with ADHD.
12/2019	Adult substance use as a function of growth in peer use across adolescence and young adulthood in the context of ADHD: Findings from the MTA.
12/2019	Depression and ADHD-Related Risk for Substance Use in Adolescence and Early Adulthood: Concurrent and Prospective Associations in the MTA.
4/2019	Predictive utility of childhood diagnosis of ICD-10 hyperkinetic disorder: adult outcomes in the MTA and effect of comorbidity.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Brooke S G Molina Research Topics

Disease

57	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 02/2022 - 06/2004
12	Substance-Related Disorders (Drug Abuse) 03/2020 - 08/2003
4	Conduct Disorder (Conduct Disorders) 03/2020 - 08/2003
3	Oppositional Defiant Disorder 03/2020 - 08/2003
3	Attention Deficit and Disruptive Behavior Disorders (Disruptive Behavior Disorder) 01/2016 - 04/2015
2	Alcohol-Related Disorders 01/2021 - 11/2010
2	Marijuana Use 03/2020 - 03/2019
1	Flushing 01/2019
1	Tardive Dyskinesia 01/2017
1	Binge Drinking 04/2016
1	Weight Gain 01/2014
1	Antisocial Personality Disorder (Antisocial Personality) 01/2014

Drug/Important Bio-Agent (IBA)

34	Pemetrexed (MTA)FDA Link 02/2022 - 11/2004
8	Risperidone (Risperdal Consta)FDA LinkGeneric 01/2020 - 01/2014
4	Illicit Drugs (Recreational Drugs)IBA 03/2020 - 08/2003
3	Pharmaceutical PreparationsIBA 03/2020 - 01/2015
2	Biological ProductsIBA 11/2018 - 11/2010
2	ProlactinIBA 01/2017 - 01/2014
1	SphingolipidsIBA 01/2020
1	Prescription DrugsIBA 01/2019
1	Antipsychotic Agents (Antipsychotics)IBA 01/2019
1	Carnitine O-Palmitoyltransferase (Carnitine Palmitoyltransferase II)IBA 01/2017
1	Nicotine FDA Link 04/2016
1	Cannabinoid Receptors (Cannabinoid Receptor)IBA 01/2016
1	SmokeIBA 05/2014
1	BuffersIBA 08/2012
1	Cocaine (Cocaine HCl)IBA 07/2007

Therapy/Procedure

42	Combined Modality Therapy 02/2022 - 06/2004
2	Aftercare (After-Treatment) 08/2012 - 05/2009
1	Precision Medicine 01/2021
1	Treatment Delay 01/2021
1	Therapeutics 09/2014